BASF takes on Quick-Med’s MultiStat MMP inhibitors
BASF Beauty Care Solutions LLC and Quick-Med Technologies Inc have agreed a new multi-year worldwide manufacturing and distribution agreement under which BASF will manufacture and distribute Quick-Med’s proprietary anti-ageing MultStat technology.
BASF Beauty Care Solutions LLC and Quick-Med Technologies Inc have agreed a new multi-year worldwide manufacturing and distribution agreement under which BASF will manufacture and distribute Quick-Med’s proprietary anti-ageing MultStat technology.
MultiStat is a proprietary family of MMP (matrix metalloproteinase) inhibitors believed to represent a new frontier in anti-ageing skin care. BASF is to focus on a particular advanced and patented compound that has already been shown to significantly benefit the appearance and maintenance of skin in over 250 studies and academic papers.
MMP inhibitors have been found to be effective in broad based applications, including improving the appearance of fine lines and wrinkles associated with intrinsic or photo ageing and damage.
“As the premier supplier to the cosmetic industry, BASF is the ideal partner to achieve MultiStat’s exciting market potential,” commented J Ladd Greeno, ceo of Quick-Med. “And our exclusive rights to use this important technology in anti-ageing products should help drive our success.”
Quick-Med says it owns the exclusive right to use MMP inhibitors for key anti-ageing products based on its license agreement with the University of Michigan.
This new agreement between BASF and Quick-Med supersedes previous agreements between the two.